Background: the most important side effect of radioiodine (131I) therapy is sialoadenitis and xerostomy. Aim: to evaluate by ultrasound (US) parotid and submandibular glands after 131I therapy for differentiated thyroid cancer (DTC). Patients: 76 subjects thyroidectomised for DTC submitted to salivary glands US examination. Forty3 of them had been previously treated with 131I: 22 with 1.11 GBq (30 mCi) for remnant ablation, and 21 with higher doses (up to 44.4 GBq - 1200 mCi) for metastases. 33 subjects were studied before 131I therapy, and were the controls. Parotid and submandibular volume, homogeneity and echogenicity were determined. 131I treated patients filled a questionnaire about sialoadenitis symptoms. Results: Parotid gland volume was significantly higher in treated patients (28.3 ± 16.2 ml) than in untreated patients (20.7 ± 10.4 ml p = 0.0154) and related to the time from last 131I therapy. 3 had parotid volume <1.5 ml and complained severe xerostomy. Submandibular gland volume was similar in treated (11.2 ± 7.6 ml) and untreated patients (8.6 ± 4.2 ml, p = 0.0602). Homogeneity and echogenicity were similar in treated and untreated patients. Sialoadenitis symptoms were reported in 26% and were related to the 131I cumulative dose. Symptoms were not related to gland volume. Hypoechogenicity and inhomogeneity of the parotids were more frequent in patients with salivary stickiness. Conclusion: parotid, but not submandibular, volume is increased after 131I treatment depending on the received activity and the time from irradiation, but not on sialoadenitis symptoms. Xerostomy is associated to gland atrophy at US.
Salivary glands US examination after radioiodine-131 treatment for differentiated thyroid cancer.
BENCIVELLI, VALTER;VITTI, PAOLO;PINCHERA, ALDO;
2013-01-01
Abstract
Background: the most important side effect of radioiodine (131I) therapy is sialoadenitis and xerostomy. Aim: to evaluate by ultrasound (US) parotid and submandibular glands after 131I therapy for differentiated thyroid cancer (DTC). Patients: 76 subjects thyroidectomised for DTC submitted to salivary glands US examination. Forty3 of them had been previously treated with 131I: 22 with 1.11 GBq (30 mCi) for remnant ablation, and 21 with higher doses (up to 44.4 GBq - 1200 mCi) for metastases. 33 subjects were studied before 131I therapy, and were the controls. Parotid and submandibular volume, homogeneity and echogenicity were determined. 131I treated patients filled a questionnaire about sialoadenitis symptoms. Results: Parotid gland volume was significantly higher in treated patients (28.3 ± 16.2 ml) than in untreated patients (20.7 ± 10.4 ml p = 0.0154) and related to the time from last 131I therapy. 3 had parotid volume <1.5 ml and complained severe xerostomy. Submandibular gland volume was similar in treated (11.2 ± 7.6 ml) and untreated patients (8.6 ± 4.2 ml, p = 0.0602). Homogeneity and echogenicity were similar in treated and untreated patients. Sialoadenitis symptoms were reported in 26% and were related to the 131I cumulative dose. Symptoms were not related to gland volume. Hypoechogenicity and inhomogeneity of the parotids were more frequent in patients with salivary stickiness. Conclusion: parotid, but not submandibular, volume is increased after 131I treatment depending on the received activity and the time from irradiation, but not on sialoadenitis symptoms. Xerostomy is associated to gland atrophy at US.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
